Lonza to Acquire Five Merck CDMO Sites in Major US Expansion
Lonza will acquire five US CDMO sites from Merck KGaA, adding bioconjugate, payload-linker, viral-vector and lipid nanoparticle capabilities.
Lonza to Acquire Five Merck CDMO Sites in Major US Expansion Read More »
